What changed
$TMO — Provides scientific instruments, reagents, and lab services.
🎯 Q1 FY26 | Rev $11B | EPS $5.44 vs $5.24 🟢 | Margin 21.8%
💡 Consensus expects a gradual recovery in life sciences tools spending, but TMO's Q1 beat (EPS $5.44 vs $5.24) and raised guidance (FY EPS $24.86 vs prior $24.50) signal stronger-than-anticipated demand from biopharma and academic customers, plus margin expansion from PPI.
🏢 Business Quality: 9/10 | Valuation: fair
📉 Reward/Risk: Upside 17% to $550 vs downside 10% to $425 (if macro slowdown or guidance cut). Ratio: 1.7:1.
🔮 Catalyst: Q2 2026 earnings (late July): expect EPS ~$6.37 vs $6.37 consensus, but revenue beat driven by bioprocessing and electron microscopy. Key metric: organic revenue growth >5%. Failure signal: organic growth <3% or margin compression.
💰 Entry: Current price $472.96 is attractive; ideal entry below $460 (3% downside).
Also in play: $VZ $T $TMUS $CHTR $CMCSA $ERIC